前列腺癌177Lu-PSMA-617放射配体疗法研发历程、药物特性及临床应用OA
Development,pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer
镥-177(177Lu)-前列腺特异性膜抗原(prostate specific membrane antigen,PSMA)-617是一种靶向 PSMA的新型放射配体疗法(radioligand therapy,RLT)的小分子药物.该药物通过靶向递送177Lu释放的 β-射线实现 PSMA阳性前列腺癌细胞的精准杀伤,已在多个国家和地区获批用于 PSMA阳性转移性去势抵抗性前列腺癌的治疗,为前列腺癌患者的治疗提供了新选择.本文综述了177Lu-PSMA-617的研发历程、药物特性和临床应用现状,为 RLT药物治疗前列腺癌的临床实践提供理论参考.
Lutetium-177(177Lu)-prostate specific membrane antigen(PSMA)-617 is a small-molecule radioligand therapy(RLT)drug targeting PSMA.By selectively delivering the β-radiation emitted by 177Lu to PSMA-positive prostate cancer cells,it induces tumor cell death.The agent has been approved in multiple nations and regions for the treatment of PSMA-positive metastatic castration-resistant prostate cancer,thereby expanding therapeutic options for this patient population.This review outlines the development,pharmacological properties,and current clinical applications of 177Lu-PSMA-617,aiming to provide a theoretical basis for the clinical practice of RLT in prostate cancer treatment.
吕靖;刘国兵;石洪成
复旦大学附属中山医院核医学科,上海 200032复旦大学附属中山医院核医学科,上海 200032复旦大学附属中山医院核医学科,上海 200032
医药卫生
前列腺癌放射配体疗法前列腺特异性膜抗原镥-177177Lu-PSMA-617
prostate cancerradioligand therapyprostate specific membrane antigenlutetium-177177Lu-PSMA-617
《中国临床医学》 2026 (2)
321-329,9
评论